Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Prophylactic cancer chemotherapy may have first trials soon The first clinical trials in cancer chemoprevention could begin within a year under the auspices of the National Cancer Institute (NCI), in Bethesda, Md. The idea of cancer chemoprevention is to use pharmacologic means to stop or reverse preneoplastic changes in tissue before the ultimate progression to tumor formation becomes irreversible. The principal chemical to be tested could be 13-cis-retinoic acid, a synthetic analog of vitamin A, that would be administered to persons at high risk of cancer. "I think there are people in the United States at sufficiently high risk of cancer that one could justifiably consider the possibility of putting them on a regimen of 13-cis-retinoic acid on a prophylactic basis," says Michael B. Sporn, MD, chief of the Lung Cancer Branch at NCI. Among the possible candidates for such treatment are asbestos workers and
JAMA – American Medical Association
Published: Apr 5, 1976
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.